Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Arthrotec forte

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
3 3
3 3

Misoprostol Testmiljö

Misoprostol

Klass : 3

Visa all info

Skriv ut

Kontakta oss

  1. Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Clin Dysmorphol. 1993;2:76-80.

  2. Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases. Birth Defects Research Part A 2003;67:1002-7.

  3. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV et al. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.

  4. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugamaya SM et al. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 2000;95:302-6.

  5. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.

  6. Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 2003;123(1):72-8.

  7. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105(5Pt2):1203-5.

  8. Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.

  9. Pastuszak AL, Schuler L, Speck-Martins CE et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.

  10. da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22:666-71.

  11. Schuler L, Pastuszak A, Sanseverino TV et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.

  12. Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council may 2003 New York [www]. [cited 2012-06-01]. http://gynuity.org/downloads/mtg_rep_miso_teratogen_en.pdf

  13. Andersen JT, Mastrogiannis D, Andersen NL, Petersen M, Broedbaek K, Cejvanovic V et al. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet. 2016;294:245-50.

  14. Blanch G, Quenby S, Ballantyne ES et al. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. BMJ 1998;316:1712-3.

  1. Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. Clin Dysmorphol. 1993;2:76-80.
  2. Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: Neuropathological study of three cases. Birth Defects Research Part A 2003;67:1002-7.
  3. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV et al. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 2000;95:297-301.
  4. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugamaya SM et al. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 2000;95:302-6.
  5. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-23.
  6. Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 2003;123(1):72-8.
  7. Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 2005;105(5Pt2):1203-5.
  8. Gonzalez CH, Marques-Dias MJ, Kim CA et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998;351:1624-7.
  9. Pastuszak AL, Schuler L, Speck-Martins CE et al. Use of misoprostol during pregnancy and Mobius' syndrome in infants. N Engl J Med 1998;338:1881-5.
  10. da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol. 2006;22:666-71.
  11. Schuler L, Pastuszak A, Sanseverino TV et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999;13:147-51.
  12. Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council may 2003 New York [www]. [cited 2012-06-01]. http://gynuity.org/downloads/mtg_rep_miso_teratogen_en.pdf
  13. Andersen JT, Mastrogiannis D, Andersen NL, Petersen M, Broedbaek K, Cejvanovic V et al. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. Arch Gynecol Obstet. 2016;294:245-50.
  14. Blanch G, Quenby S, Ballantyne ES et al. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. BMJ 1998;316:1712-3.
2 2
2 2

Diklofenak – systemiskt Testmiljö

Diklofenak – systemiskt

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824-9.

  2. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology. 1997;56:282-92.

  3. Souter D, Harding J, McCowan L, O´Donnell C, McLeay E, Baxendale H. Antenatal indomethacin - adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998;38:11-6.

  4. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353.

  5. Hernández-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110 Suppl 3A:20S-7S.

  6. Dathe K, Frank J, Padberg S, Hultzsch S, Beck E, Schaefer C. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. BMC Pregnancy Childbirth. 2022;22(1):666.

  7. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.

  8. Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97:312-6.

  9. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.

  10. UK Teratology Information Service (UKTIS). USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) IN PREGNANCY 2023 September Version 40. UKTIS [www]. [cited 2024-03-13].

  11. Lopes LM, Carrilho MC, Francisco RP, Lopes MA, Krebs VL, Zugaib M. Fetal ductus arteriosus constriction and closure: analysis of the causes and perinatal outcome related to 45 consecutive cases. J Matern Fetal Neonatal Med. 2016;29(4):638-45.

  12. Dos Santos CS, Silva PV, Castelo R, Tiago J. Premature closure of ductus arteriosus after a single dose of diclofenac during pregnancy. BMJ Case Rep. 2021;14(6):.

  13. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-70.

  14. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79.

  15. Ericson A, Kallen BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5.

  16. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Brit Med J 2003;327:368-72.

  17. Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183:1713-20.

  18. Nielsen GL, Skriver MV, Pedersen L Sorensen HT. Danish group reanalyses miscarriage in NSAID users. Brit Med J 2004;328:109.

  19. Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186:E177-82.

  20. Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120:113-22.

  21. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-61.

  22. Ferencz C, C.-V.A., Loffredo CA, Wilson PD, Genetics and environmental risk factors of major cardiovascular malformations: the Baltimore-Washington Infant Study: 1981–1989. Perspect Ped Cardiol 5. Vol. 5. 1997, New York: Futura Publishing Comp., Inc.

  23. Cleves MA, Savell VH, Raj S, Correa A, Werler MM, Hobbs CA. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Def Res Part A 2004;70:107-13.

  1. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824-9.
  2. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology. 1997;56:282-92.
  3. Souter D, Harding J, McCowan L, O´Donnell C, McLeay E, Baxendale H. Antenatal indomethacin - adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998;38:11-6.
  4. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353.
  5. Hernández-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110 Suppl 3A:20S-7S.
  6. Dathe K, Frank J, Padberg S, Hultzsch S, Beck E, Schaefer C. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. BMC Pregnancy Childbirth. 2022;22(1):666.
  7. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.
  8. Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97:312-6.
  9. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.
  10. UK Teratology Information Service (UKTIS). USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) IN PREGNANCY 2023 September Version 40. UKTIS [www]. [cited 2024-03-13].
  11. Lopes LM, Carrilho MC, Francisco RP, Lopes MA, Krebs VL, Zugaib M. Fetal ductus arteriosus constriction and closure: analysis of the causes and perinatal outcome related to 45 consecutive cases. J Matern Fetal Neonatal Med. 2016;29(4):638-45.
  12. Dos Santos CS, Silva PV, Castelo R, Tiago J. Premature closure of ductus arteriosus after a single dose of diclofenac during pregnancy. BMJ Case Rep. 2021;14(6):.
  13. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-70.
  14. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79.
  15. Ericson A, Kallen BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5.
  16. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Brit Med J 2003;327:368-72.
  17. Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183:1713-20.
  18. Nielsen GL, Skriver MV, Pedersen L Sorensen HT. Danish group reanalyses miscarriage in NSAID users. Brit Med J 2004;328:109.
  19. Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186:E177-82.
  20. Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120:113-22.
  21. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-61.
  22. Ferencz C, C.-V.A., Loffredo CA, Wilson PD, Genetics and environmental risk factors of major cardiovascular malformations: the Baltimore-Washington Infant Study: 1981–1989. Perspect Ped Cardiol 5. Vol. 5. 1997, New York: Futura Publishing Comp., Inc.
  23. Cleves MA, Savell VH, Raj S, Correa A, Werler MM, Hobbs CA. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Def Res Part A 2004;70:107-13.